Table 3. Critical Evaluation of Methodology of Studies Included in This Review.
| IHC Targets | Number
of HS Patients |
Number
of Controls |
Samples
Analyzed |
Age/Sex
Matched Controls |
Stratified by
severity |
Stratified by
lesion site |
Stratified
by Co- morbidities |
Stratified by
Treatment |
Immunostaining Intensity
Assessment |
Study
Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| α-MSH, LL37, S100A7, MIF, TNF-α, hBD3,
lysozyme |
18 | 12 | L | N | NR | N | N | N | Quantitiative
Immunohistomorphometry (Image J Software) |
14 |
| IL36 | 15 | 15 | L, PL | NR | NR | N | N | N | Present/ Absent | 6 |
| CD3, CD56 LL37 | 24 | 9 | L | Y | NR | NR | N | Y (untreated) | Semiquantitative (0-3) | 29 |
| CD1a, CD4, CD8 CD20, CD56, Factor XIIIa, IL17,
NLRP3, Caspase-1 |
22 | Yes (NR) | L, PL, U, C | NR | N | N | N | N | Cell Counting square grid
x400 magnification |
30 |
| IL-23, IL-12, CD68, CD4 | 10 | 8 | L, C | N | N | N | N | Y (ceased
3/52 prior) |
Positive stained cells per
mm 2 |
32 |
| IL-32 | 20 | 10 | L, C, S | N | Y | N | N | Y (ceased
8/52 prior) |
Semiquantitative (+ to ++++) | 4 |
| IL-36 | 25 | 7 | L, C, S | N | N | N | N | Y (ceased
3/25 prior) |
Semiquantitative (+ to ++++) | 5 |
| LCN2 | 10 | 16 | L | Y | N | N | N | N | Present/ Absent | 31 |
| CD11c | 20 | 6 | L | N | Y | N | N | Y | Semiquantitative (+ to ++++) | 12 |
| MMP2 hBD2 TNF-α | 14 | 2 | L, C | N | N | Y | N | N | Semiquantitative ((+ to
++++) |
13 |
| CD3, CD4, CD8, CD68 CD79 CD56 | 60 | Yes (NR) | L,C | N | N | Y | N | N | Present or Absent | 33 |
| CD3, CD4, CD8, CD20, CD138, CD14, CD68,
CD11c |
9 | Yes (NR) | L,C | N | N | N | N | N | Semiquantitative (+ to ++++) | 11 |
| GCDFP-15, CD15, Lysosyme, S100, Ca19-9,
HMB45 |
13 | 3 | L,C | N | N | Y | N | N | Semiquantitative (+ to ++++) | 34 |
| CD29, CTx-FITC | 5 | 4 | L,C | N | N | Y | N | N | Present or Absent | 35 |
| AE1/AE3/PKC26/ Enhanced Alkaline
Phosphatase |
50 | Y (NR) | L,C | N | N | Y | N | N | Present or Absent | 36 |
| K1, K10, K14, K16,k17, K19, | 14 | 1 | L,C | N | N | Y | N | N | Semiquantitative (+ to ++++) | 37 |
| Desmoplakin 1,2, Plakoglobin, Plakophilin 1,2,
Desmoglein 1,2,3, Desmocollin 1,2,3,K2e, K4, K5, K6, K7, CK8,CK9, CK10, K13, K13/15/16, K14, K17,K19, K20 Ki67 |
15 | Y (NR) | L,C | N | N | N | N | N | Semiquantitative (+ to ++++) | 38 |
| ER, AR | 22 | 10 | L,C | N | N | Y | N | N | Semiquantitative (+ to ++++) | 39 |
| TLR2, CD3, CD19, CD56,CD68, CD11c, CD1a,
CD206, CD207, CD209 |
9 | Y (NR) | L,C | N | N | N | N | N | Semiquantitative (+ to ++++) | 40 |
| TLR 2,3,4,7,9,ICAM-1, TNF-α, IL-6, IL-10, TGF-β,
α-MSH, hBD2, hBD4 IGF-1 |
12 | Y (NR) | L,PL | N | N | N | N | N | Semiquantitative (+ to ++++)
Epidermis Only |
41 |
| hBD3, S100A7, RNase7 | 36 | 57 | L,C | N | N | N | N | N | Semiquantitative (+ to ++++) | 42 |
| MMP8 | 10 | 8 | L,C | Y | N | N | N | N | Semiquantitative (+ to ++++) | 43 |
| 494 | 168 | 3/22 | 2/22 | 7/22 | 0/22 | 5/22 |
Table 3: Critical Evaluation of Methodology of Studies Included in This Review Key:L= Lesional, PL= Perilesional, U= Uninvolved, C= Control S=Serum, Y=Yes, N=No, NR= Not Reported, CTx-FITC =Cholera Toxin